Verition Fund Management’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
Other funds holding JAZZ
VPM
VCM
EC
Verition Fund Management's JAZZ Position: Q1 2026 in Review
Verition Fund Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 40,590 shares — an estimated $6.9M sold.
Verition Fund Management first reported a position in JAZZ in Q2 2013 and held it in 27 quarters. The position peaked at $31.3M in Q1 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Verition Fund Management reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Verition Fund Management sold 40,590 Jazz Pharmaceuticals shares in Q1 2026, an estimated $6.9M.
- Verition Fund Management first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 27 quarters.
- Verition Fund Management's Jazz Pharmaceuticals position peaked at $31.3M in Q1 2025.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.